Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model
| Autor: | Kei Kawaguchi, Ryusei Matsuyama, Zhiying Zhang, Kentaro Miyake, Shree Ram Singh, Robert M. Hoffman, Scott D. Nelson, Takashi Higuchi, Masuyo Miyake, Tasuku Kiyuna, Yukihiko Hiroshima, Sahar Razmjooei, Takafumi Kumamoto, Sintawat Wangsiricharoen, Hiromichi Oshiro, Michael Bouvet, Sant P. Chawla, Itaru Endo, Takashi Murakami, Yunfeng Li |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Leiomyosarcoma
0301 basic medicine medicine.medical_specialty medicine.medical_treatment Biophysics Urology Mice Nude Docetaxel Palbociclib Deoxycytidine Biochemistry Pazopanib Mice 03 medical and health sciences 0302 clinical medicine Recurrence Antineoplastic Combined Chemotherapy Protocols medicine Animals Humans Doxorubicin Neoplasm Metastasis Molecular Biology Peritoneal Neoplasms Salvage Therapy Chemotherapy business.industry Cell Biology medicine.disease Gemcitabine Recurrent Leiomyosarcoma Tumor Burden Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Heterografts business medicine.drug |
| Zdroj: | Biochemical and Biophysical Research Communications. 509:1041-1046 |
| ISSN: | 0006-291X |
| DOI: | 10.1016/j.bbrc.2019.01.046 |
| Popis: | There are no effective treatments for leiomyosarcoma (LMS) spreading intraabdominally. The aim of this study was to develop precision chemotherapy for recurrent peritoneal LMS metastases in a patient-derived orthotopic xenograft (PDOX) model. The LMS PDOX models were established orthotopically on the dome of the bladder of nude mice. The LMS PDOX models were randomized into 6 groups when the tumor volume reached 80 mm3: G1: untreated control; G2: doxorubicin (DOX) (DOX: i.p., 3 mg/kg, weekly, 3 weeks); G3: DOX combined with olaratumab (OLA) (DOX: i.p., 3 mg/kg, weekly, 3 weeks; OLA: i.p., 40 mg/kg, 3 times/week, 3 weeks); G4: gemcitabine (GEM) combined with docetaxel (DOC) (GEM: i.p., 100 mg/kg, weekly, 3 weeks; DOC: i.p., 20 mg/kg, weekly, 3 weeks); G5: pazopanib (PAZ) (PAZ: p.o., 100 mg/kg, daily, 3 weeks); G6: palbociclib (PAL) (PAL: p.o., 100 mg/kg, daily, 3 weeks). All mice were sacrificed on day 22. Body weight was assessed twice a week. Tumor volume was measured on day 0 and day 22. Although all regimens had a significant efficacy compared to the untreated group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect